Ensartinib after chemoradiation for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether the drug ensartinib can help prevent cancer from returning after standard chemoradiation in people with stage III ALK-mutated non-small cell lung cancer that cannot be removed by surgery. Enrolling those who have completed chemoradiation within the past 6 weeks without their cancer getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have stage III non-small cell lung cancer (NSCLC) that cannot be surgically removed and has an ALK gene mutation
- You have finished platinum-based chemoradiation (concurrent or sequential) within the last 6 weeks and your cancer hasn't progressed
- You are in good physical condition (ECOG performance status 0 or 1)
- You have not been treated before with any ALK-targeted therapy like crizotinib, alectinib, or brigatinib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral targeted therapy (Ensartinib) after surgery for patients with stage I ALK-positive lung cancer who have certain high-risk features. The goal is to see if it helps prevent cancer from returning.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
This study looks at how well the drug Ensartinib works when given before surgery to people with a certain type of lung cancer (ALK-positive NSCLC) that can be removed. The goal is to see if it helps shrink the tumor and is safe to take.
This Phase 3 trial tests whether ensartinib given after surgery can lower the risk of lung cancer coming back in people with ALK-positive non-small cell lung cancer. You may be eligible if your tumor was completely removed and your recovery and lab tests meet specific requirements.
This trial tests the targeted therapy drug ensartinib given after surgery to prevent lung cancer from coming back. It is only for people whose tumor has an ALK gene change and who are in early to moderately advanced stages after complete removal.
This trial compares ensartinib with standard platinum-based chemotherapy as “adjuvant” treatment—medicine given after surgery to lower the chance the cancer comes back. It’s for people with stage IIA to IIIA ALK-positive non-small cell lung cancer who had their tumor surgically removed.
Hear when a new Ensartinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.